1 / 15

dd/mm/yyyy

Urology SSG 22nd April 2015 Research Wendy Cook, Research Delivery Manager Dr Mohini Varughese, Urology Subspecialty Lead. dd/mm/yyyy. South West Peninsula CRN. Division 1- Cancer - Contacts. Duncan Wheatley, Clinical Specialty Lead duncan.wheatley@rcht.cornwall.nhs.uk 01872 258312

anancy
Download Presentation

dd/mm/yyyy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Urology SSG 22nd April 2015ResearchWendy Cook, Research Delivery ManagerDr Mohini Varughese, Urology Subspecialty Lead dd/mm/yyyy

  2. South West Peninsula CRN

  3. Division 1- Cancer - Contacts • Duncan Wheatley, Clinical Specialty Lead duncan.wheatley@rcht.cornwall.nhs.uk01872 258312 • 13 sub speciality leads • Wendy Cook, Research Delivery Manager wcook1@nhs.net01392 406995 • Ann Courtman, Administrator ann.courtman@nhs.net 01392 406966 • Mohini Varughese Urology sub specialty leadMohini.Varughese@tst.nhs.uk01823 342417

  4. NIHR Cancer Research Objectives • Increase the opportunities for cancer patients to take part in research studies, regardless of where they live • Develop action plan to increase access in each subspecialty (e.g by opening studies, increasing awareness and forming referral pathways for access to research)

  5. NIHR Cancer Research Objectives • Increase the number of cancer patients participating in studies, to support the national target of 20% cancer incidence • SW Peninsula Cancer Incidence 12,580 • 20% = 2,516 pts • Current performance – 1535pts 12.2% • Increase the number of cancer patients participating in interventional trials, to support the national target of 7.5% cancer incidence • 7.5% = 944 pts • Current performance – 714pts 5.7% This is measured on 11 months data from ODP (open data platform)

  6. NIHR Cancer Research Objectives Deliver a Portfolio of studies including challenging trials in support of national priorities: ● Cancer Surgery ● Radiotherapy ● Rare cancers (cancers with incidence <6/100,000 year) ● Children’s Cancer & Leukaemia and Teenagers & Young Adults

  7. What we need to achieve in each subspecialty group • 13 named cancer sub specialty leads with a defined portfolio of studies • Highlight, promote studies • Promote referral pathways throughout the network • Research Subspecialty Lead • Participate in national meetings to collaborate with other sub-speciality leads identify studies to bring to the region • Connection with CSG’s, feedback re sub specialty portfolio and availability of trials for all. • MV Currently considering best way to feedback locally ?two monthly webinar/ teleconference update

  8. Network Recruitment

  9. National Recruitment

  10. Key Messages (1) • Recruitment in SW lower than average, as compared to nationally for urology trials • Many examples of very high recruiting urology trials across network however. • Need to consider ‘big hitters’ and ‘easy wins’ e.g. genetics studies and biopsy studies • Recruitment to bladder and renal studies significantly less than prostate (similar nationally) • Renal: • Key priority is to open STAR

  11. Key messages – bladder cancer (2) • Non muscle invasive bladder cancer: • PHOTO and Caliber; aim to open more sites in network • Muscle invasive disease: • RAIDER (RT) • CCG considering feasibility of validated biomarker study indicating sensitivity to radical RT (vs surgery if pts do not demonstrate this biomarker). • Would local surgeons feel happy to randomise to this trial? Need to avoid repeat of SPARE trial (early closure). Valid research question? • Metastatic disease: • ATLANTIS; due to open last quarter 2015. All encompassing biomarker study • Push to open throughout the Network

  12. Key Messages (3) • Prostate portfolio • Nationally and locally very good recruitment. • STAMPEDE is ‘bread and butter’, aim to open across all Trusts • Testis • I need to know network Testis leads, to inform CSG of contacts to permit direct communication • Two international studies to open latter half of year; • TIGER (relapsed disease randomised to high dose chemo and autologous stem cell transplant) • Accelerated BEP trial in poor prognosis pts at presentation.

  13. Portfolio Map Link http://csg.ncri.org.uk/portfolio-maps/ See separate attachment for complete national recruitment by all 15 networks

  14. Cancer Research Symposium From Clinical Trials to Clinical Practice Hosted by RD&E Jenny Forrest & Kate Scatchard, Consultant Clinical Oncologists at Gipsy Hill Hotel, Exeter Friday 15th May 2015 Contact ann.courtman@nhs.net for more information on 01392 406996

  15. Thank you Any questions?

More Related